Entrada Therapeutics Inc. has released a corporate presentation detailing its significant clinical momentum throughout 2025. The company anticipates having four active clinical programs by the end of the year, with notable advancements in its Duchenne muscular dystrophy (DMD) franchise. Clinical studies for ENTR-601-44 have been authorized in the UK, EU, and US, while ENTR-601-45 has been authorized in the UK and EU. Additionally, ENTR-601-50 is on track for global regulatory filings in the second half of 2025. Entrada is also advancing its preclinical pipeline, which includes programs targeting ocular diseases. The company maintains a strong financial position, with a cash balance of approximately $383 million, expected to support operations into the second quarter of 2027. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。